Last reviewed · How we verify
Mucolox® alone
Mucolox is a mucus-thinning agent that reduces mucus viscosity to improve clearance and airway function in patients with excessive or thick mucus production.
Mucolox is a mucus-thinning agent that reduces mucus viscosity to improve clearance and airway function. Used for Chronic obstructive pulmonary disease (COPD) with excessive mucus production, Cystic fibrosis, Bronchiectasis.
At a glance
| Generic name | Mucolox® alone |
|---|---|
| Sponsor | University of Alberta |
| Drug class | Mucolytic agent |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Mucolox works by breaking down the glycoprotein and mucopolysaccharide components of mucus, reducing its viscosity and making it easier to expectorate. This mechanism helps restore normal mucociliary clearance in conditions characterized by abnormally thick or copious mucus secretions, improving airflow and reducing airway obstruction.
Approved indications
- Cystic fibrosis
- Chronic bronchitis with excessive mucus production
Common side effects
- Bronchospasm
- Hemoptysis
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mucolox® alone CI brief — competitive landscape report
- Mucolox® alone updates RSS · CI watch RSS
- University of Alberta portfolio CI